HTG Molecular Diagnostics, Inc. develops and markets technology platforms that facilitate the routine use of complex molecular profiling. The company's HTG Edge and HTG EdgeSeq platforms consist of instrumentation, consumables, and software analytics that are used in molecular profiling applications, including tumor profiling, biomarker development and prospectively, and molecular diagnostic testing. The company's platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on various biological samples. It provides molecular profiling panels targeting late stage drug development programs with potential breakthrough therapies, such as immuno-oncology. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors or sales agents in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.